Activated monocytes as a therapeutic target to attenuate vascular inflammation and lower cardiovascular disease-risk in patients with type 2 diabetes: A systematic review of preclinical and clinical studies - 16/01/22
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 11 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Low grade inflammation is associated with the progression of atherosclerosis. Patients with type 2 diabetes (T2D) have altered cholesterol levels, which are targeted by free radicals to promote lipid peroxidation. Elevated levels of monocyte-associated cytokines such as interleukin (IL)-6, monocyte chemoattractant protein 1 (MCP-1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and tumor necrosis factor-alpha (TNF-α), subsequently drive endothelial tissue injury. In fact, the levels of circulating platelet-monocyte aggregates in patients with T2D is a robust marker for atherosclerosis and a cardiovascular disease (CVD)-risk factor. To identify eligible studies, we searched the major online databases using PubMed and Google Scholar. The cumulative evidence synthesized in the current review suggests that, traditional therapies which include thiazolidinediones, statins and some calcium channel blockers can be useful in the primary prevention of atherosclerosis by inhibiting the formation of monocyte-derived microparticles, and pro-inflammatory cytokines such as IL-6, TNF-α, MCP-1, and NF-κB in patients with T2D. Future studies are needed to ascertain whether the combination of dietary interventions and glucose or lipid lowering agents can provide an enhanced cardioprotection in patients with T2D.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Low grade inflammation is associated with the progression of atherosclerosis in type 2 diabetes (T2D). |
• | Patients with T2D have elevated cholesterol, which react with free radicals to promote atherosclerosis. |
• | Circulating platelet-monocyte aggregates in T2D are consistent with atherosclerosis. |
• | Traditional therapies like thiazolidinediones and statins target inflammation to ameliorate atherosclerosis in T2D. |
Abbreviations : CVD, CAD, CRP, DPP-4, Erk, GSH px, GSH, HbA1c, HFD, HDL, IKKβ, S597, IR, IL-6/8/10/1β, MLL1, MCP-1, NAC, vitamin B₃, NF-κB, PDMP, TBARS, TLR-4/ TLR-2, TNF-α, T2D
Keywords : Type 2 diabetes, Cardiovascular disease, Vascular function, Monocytes, Inflammation., Therapeutic target
Plan
Vol 146
Article 112579- février 2022 Retour au numéro
Article précédent
- AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation
- Maliheh Entezari, Danial Hashemi, Afshin Taheriazam, Amirhossein Zabolian, Shima Mohammadi, Farima Fakhri, Mehrdad Hashemi, Kiavash Hushmandi, Milad Ashrafizadeh, Ali Zarrabi, Yavuz Nuri Ertas, Sepideh Mirzaei, Saeed Samarghandian
- The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review
- Felix Zulhendri, Conrad O. Perera, Steven Tandean, Rizky Abdulah, Herry Herman, Andreas Christoper, Kavita Chandrasekaran, Arfiza Putra, Ronny Lesmana
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?